Synergy Pharmaceuticals commences pivotal plecanatide CIC trial

Synergy Pharmaceuticals (SGYP +2.5%) initiates a Phase 3 pivotal trial of plecanatide in CIC. Primary endpoint: Proportion of patients who are overall responders.

The company is confident the GC-C agonist is "best-in-class."

Top-line data from an ongoing Phase 2b study of plecanatide in IBS-C is due in Q1 2014. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs